« Return to News | Awards & Advancement

DIA names Stephen P. Spielberg editor-in-chief of TIRS journal

Friday, January 25, 2013 11:59 AM

DIA, a neutral, global, professional and member-driven association of nearly 18,000 professionals, announced the arrival of Stephen P. Spielberg, M.D., Ph.D., as editor-in-chief of the newly launched, official DIA peer-reviewed scientific journal, Therapeutic Innovation & Regulatory Science (TIRS).

Spielberg comes to DIA on the heels of his tenure at the FDA, where he has served since September 2011 as deputy commissioner for medical products and tobacco. With a career spanning more than 35 years in medicine, academia, the pharmaceutical industry and regulatory affairs, Spielberg brings experience and leadership to DIA's journal. Spielberg formerly served as executive director of exploratory biochemical toxicology and of clinical and regulatory development at Merck Research Laboratories, and was vice president for pediatric drug development at Johnson & Johnson.

More recently, he was the chair in pediatric pharmacogenomics and director of the Center for Personalized Medicine and Therapeutic Innovation at Children's Mercy Hospital, Kansas City, Mo., as well as the dean of Dartmouth Medical School and vice president for health affairs at Dartmouth College. Spielberg also served on the board of directors of the Foundation for the National Institutes of Health, the FDA science board advisory committee and the executive board of Observational Medical Outcomes Partnership. Spielberg also brings a wealth of editorial experience to DIA. He previously was associate editor of Drug Metabolism and Disposition and serves on the editorial boards of multiple pediatric and pharmacology journals. 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013
Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings
Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving
Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.